United States:
FDA Establishes Docket On Patient Participation In Medical Product Discussions
25 November 2014
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
In the November 4, 2014, Federal Register, FDA
announced a public docket for comments on Patient Participation in
Medical Product Discussions under FDASIA. FDA seeks input from
stakeholders on how to obtain the views of patients during the
medical product development process and ways to consider
patients' perspectives during regulatory discussions.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
Planning For The BIOSECURE Act
Foley Hoag LLP
Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies...
